Amnio Technology is a leading brand in the field of regenerative medicine, dedicated to optimizing the regenerative potential and clinical use of amniotic tissue. Founded in 2012, the company specializes in the development, processing, and distribution of innovative allografts that provide regenerative therapies to improve the quality of life. One of Amnio Technology's key products is the PalinGen® line, which includes the Membrane, Hydromembrane, XPlus Membrane, and XPlus Hydromembrane.

These products are manufactured without the need for fetal sacrifice, and recovery is performed with maternal consent during elective Cesarean delivery. This ethical approach ensures the highest standard of quality and safety. With over 10 years of experience, Amnio Technology is committed to compliance, quality, and continuous improvement.

Their products meet or exceed the rigorous standards set by the FDA and are manufactured in an FDA Registered and American Association of Tissue Banks accredited facility. Driven by their mission to enhance the gift of human birth tissue donation, Amnio Technology strives to advance the science of regenerative medicine and introduce new amniotic tissue allografts and technologies to treat patients in need